Mer­ck KGaA touts FDA 'break­through' sta­tus, block­buster po­ten­tial in bid to woo in­vestors

Mer­ck KGaA set out to woo in­vestors to­day by bur­nish­ing its pipeline prospects and spot­light­ing its drug can­di­date in the long-run­ning race to re­lease a treat­ment for a par­tic­u­lar­ly ag­gres­sive form of lung can­cer — in­sist­ing that they have a block­buster up­side in adding new rev­enue over the next 3 years.

Mer­ck KGaA has re­ceived FDA break­through ther­a­py sta­tus for tepo­tinib, a treat­ment for MET ex­on 14 skip­ping-mu­tat­ed non-small cell lung can­cer (NSCLC), join­ing No­var­tis’ cap­ma­tinib and a Pfiz­er treat­ment (Xalko­ri) in MET NSCLC drugs with ‘break­through’ sta­tus.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER